Ars Pharmaceuticals Inc (SPRY) Stock Price, Quote & News

Company Profile

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 858 771 9307

Website: ars-pharma.com

Address:

11682 El Camino Real, Suite 300, San Diego, United States

Aciputes Aug. 11 at 9:51 AM

$SPRY No, thanks 🙂

0 · Reply

OnlyUp01 Aug. 10 at 5:14 PM

$SPRY Bags getting a bit heavier? Still time to make up your losses in AQST. You're most welcome.

1 · Reply

ae1213 Aug. 10 at 3:39 PM

$AQST $SPRY ohh silly sally is back from the Jersey shore all refreshed for a new pump. No competition? 10$ sp? - you kids are so funny. Just remember, it went from 7.50 down to 3.80 just like that! Must be a “ regulatory stage”!

0 · Reply

BigGainTom Aug. 10 at 1:33 PM

$SPRY Due to likelihood of impending approval for Anaphylm, SPRY should be priced at $2-$4 per share... Neffy will have zero moat and intense competition by a better product.

1 · Reply

Goodstockday Aug. 10 at 1:15 PM

$SPRY investors need to know that the Anaphylm (oral film) data is back and it looks strong. Anaphylm now has a clean and quick path for approval in 2027. Yet, with this data, late 2026 even seems possible.

1 · Reply

BiotechGoldenEra Aug. 10 at 3:14 AM

$SPRY damn

0 · Reply

omega42 Aug. 9 at 9:03 PM

$FLNC $FSLY $LNTH $OCUL $SPRY no they don’t. They r falling off the cliff

0 · Reply

BioStick123 Aug. 7 at 1:56 PM

$SPRY cheap here. We have CSU data in a few months, and CVS formulary Jan.

2 · Reply

MrBean1234 Aug. 7 at 12:30 PM

$SPRY all about margins tho…need to hope a large majority of the scripts are thru no PA/fully covered insurance….we’ll see next week. GLTA

0 · Reply

MrBean1234 Aug. 7 at 12:14 PM

$SPRY hearing 6.4 percent TRX and 6.2 percent NRX week of 8/1…think they said 9k TRX and 7.6k NRX…a steal right here folks…good luck to all

1 · Reply

Kaplan Fox Notifies ARS Pharmaceuticals Inc. (SPRY) Investors of an Upcoming Lead Plaintiff Deadline on October 5, 2026

Aug 6, 2026, 6:45 PM EDT - 4 days ago

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY

Aug 3, 2026, 7:30 AM EDT - 7 days ago

ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results

2026-07-07T20:50:12.000Z - 4 weeks ago

ARS Pharmaceuticals announces CEO succession

SNY

Jul 7, 2026, 4:30 PM EDT - 4 weeks ago

ARS Pharmaceuticals Announces CEO Succession

2026-06-24T20:20:29.000Z - 6 weeks ago

ARS reports no new commercial formulary additions, coverage decisions for neffy

Jun 24, 2026, 4:05 PM EDT - 6 weeks ago

ARS Pharmaceuticals Provides Commercial and Financial Updates

2026-05-28T13:22:59.000Z - 2 months ago

ARS Pharmaceuticals price target raised to $30 from $12 at Cantor Fitzgerald

May 15, 2026, 8:30 AM EDT - 3 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q1 2026

May 15, 2026, 8:30 AM EDT - 3 months ago

ARS Pharmaceuticals Earnings release: Q1 2026

May 15, 2026, 8:30 AM EDT - 3 months ago

ARS Pharmaceuticals Quarterly report: Q1 2026

2026-05-15T10:07:53.000Z - 3 months ago

ARS Pharmaceuticals reports Q1 EPS (61c), consensus (54c)

May 15, 2026, 6:00 AM EDT - 3 months ago

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

May 13, 2026, 8:00 AM EDT - 3 months ago

ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President

May 7, 2026, 8:00 AM EDT - 3 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results

Apr 29, 2026, 8:00 AM EDT - 3 months ago

ARS Pharmaceuticals Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

ARS Pharmaceuticals Proxy statement: Proxy filing

2026-04-15T10:11:10.000Z - 4 months ago

ARS Pharmaceuticals announces Health Canada approval of neffy 2 mg

Apr 15, 2026, 6:05 AM EDT - 4 months ago

neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

2026-04-09T11:14:32.000Z - 4 months ago

ARS Pharmaceuticals initiated with an Outperform at Northland

2026-04-09T11:13:02.000Z - 4 months ago

Northland starts disruptor ARS Pharmaceuticals with an Outperform

2026-03-27T12:16:24.000Z - 4 months ago

ARS Pharmaceuticals receives FDA approval to remove neffy 1 mg age requirement

Mar 27, 2026, 8:00 AM EDT - 4 months ago

ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label

Mar 11, 2026, 8:00 AM EDT - 5 months ago

ARS Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:30 AM EDT - 5 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 9, 2026, 8:30 AM EDT - 5 months ago

ARS Pharmaceuticals Annual report: Q4 2025

Mar 9, 2026, 8:30 AM EDT - 5 months ago

ARS Pharmaceuticals Earnings release: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 5 months ago

ARS Pharmaceuticals Slides: Corporate presentation

2026-03-09T10:05:06.000Z - 5 months ago

ARS Pharmaceuticals reports Q4 EPS (42c), consensus (44c)

Mar 9, 2026, 6:00 AM EDT - 5 months ago

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization

Feb 23, 2026, 8:00 AM EST - 6 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

Feb 10, 2026, 8:00 AM EST - 6 months ago

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

2026-02-02T13:11:39.000Z - 6 months ago

ARS Pharmaceuticals announces CHMP of EMA adopted positive opinion for EURneffy

Feb 2, 2026, 8:00 AM EST - 6 months ago

EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to

2026-01-21T13:10:51.000Z - 7 months ago

ARS Pharmaceuticals announces California eligible for neffyinSchools program

Jan 21, 2026, 8:00 AM EST - 7 months ago

California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use

2026-01-09T14:40:36.000Z - 7 months ago

ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James

AQST

2025-12-29T13:10:25.000Z - 8 months ago

ARS Pharmaceuticals announces NMPA approval for neffy 2 mg

Dec 29, 2025, 8:00 AM EST - 8 months ago

neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)

Dec 3, 2025, 2:30 PM EST - 8 months ago

ARS Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 8:00 AM EST - 9 months ago

ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

Nov 10, 2025, 8:30 AM EST - 9 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 10, 2025, 8:30 AM EST - 9 months ago

ARS Pharmaceuticals Quarterly report: Q3 2025

Nov 10, 2025, 8:30 AM EST - 9 months ago

ARS Pharmaceuticals Earnings release: Q3 2025

Nov 10, 2025, 8:30 AM EST - 9 months ago

ARS Pharmaceuticals Slides: Q3 2025

Nov 10, 2025, 6:00 AM EST - 9 months ago

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

Nov 4, 2025, 8:00 AM EST - 9 months ago

ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)

Nov 3, 2025, 2:23 PM EST - 10 months ago

UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Nov 3, 2025, 8:00 AM EST - 10 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

Nov 3, 2025, 7:45 AM EST - 10 months ago

ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 8, 2025, 8:00 AM EDT - 10 months ago

ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)

Sep 29, 2025, 4:05 PM EDT - 11 months ago

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

Sep 17, 2025, 9:00 AM EDT - 11 months ago

ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair

Sep 8, 2025, 8:00 AM EDT - 1 year ago

Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis

Sep 3, 2025, 3:55 PM EDT - 1 year ago

ARS Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 13, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Quarterly report: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

Aug 4, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results

Jul 18, 2025, 9:25 AM EDT - 1 year ago

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

Jun 4, 2025, 5:30 PM EDT - 1 year ago

ARS Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 12:20 PM EDT - 1 year ago

ARS Pharmaceuticals Transcript: 45th Annual William Blair Growth Stock Conference

Jun 2, 2025, 7:00 AM EDT - 1 year ago

ARS Pharmaceuticals Slides: Corporate Presentation

May 14, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Quarterly report: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings release: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

May 7, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

May 5, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

Apr 29, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Proxy statement: Proxy Filing

Mar 20, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 20, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Annual report: Q4 2024

Mar 20, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings release: Q4 2024

Mar 20, 2025, 7:00 AM EDT - 1 year ago

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 5, 2025, 4:10 PM EST - 1 year ago

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

Mar 3, 2025, 4:35 PM EST - 1 year ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

Feb 20, 2025, 7:02 PM EST - 1 year ago

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

Feb 18, 2025, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

Feb 12, 2025, 2:40 PM EST - 1 year ago

ARS Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Jan 15, 2025, 10:30 AM EST - 1 year ago

ARS Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 10:30 AM EST - 1 year ago

ARS Pharmaceuticals Slides: FY 2025

Jan 6, 2025, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

Dec 19, 2024, 5:25 PM EST - 1 year ago

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Dec 12, 2024, 2:32 PM EST - 1 year ago

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

Aciputes Aug. 11 at 9:51 AM

$SPRY No, thanks 🙂

0 · Reply

OnlyUp01 Aug. 10 at 5:14 PM

$SPRY Bags getting a bit heavier? Still time to make up your losses in AQST. You're most welcome.

1 · Reply

ae1213 Aug. 10 at 3:39 PM

0 · Reply

BigGainTom Aug. 10 at 1:33 PM

$SPRY Due to likelihood of impending approval for Anaphylm, SPRY should be priced at $2-$4 per share... Neffy will have zero moat and intense competition by a better product.

1 · Reply

Goodstockday Aug. 10 at 1:15 PM

1 · Reply

BiotechGoldenEra Aug. 10 at 3:14 AM

$SPRY damn

0 · Reply

omega42 Aug. 9 at 9:03 PM

$FLNC $FSLY $LNTH $OCUL $SPRY no they don’t. They r falling off the cliff

0 · Reply

BioStick123 Aug. 7 at 1:56 PM

$SPRY cheap here. We have CSU data in a few months, and CVS formulary Jan.

2 · Reply

MrBean1234 Aug. 7 at 12:30 PM

$SPRY all about margins tho…need to hope a large majority of the scripts are thru no PA/fully covered insurance….we’ll see next week. GLTA

0 · Reply

MrBean1234 Aug. 7 at 12:14 PM

$SPRY hearing 6.4 percent TRX and 6.2 percent NRX week of 8/1…think they said 9k TRX and 7.6k NRX…a steal right here folks…good luck to all

1 · Reply

LTVI Aug. 6 at 12:24 AM

$SPRY @Stocktwits Last Update Posted 2026-07-22 An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria ID NCT06927999 Sponsor ARS Pharmaceuticals, Inc. Information provided by ARS Pharmaceuticals, Inc. (Responsible Party) https://clinicaltrials.gov/study/NCT06927999

0 · Reply

LTVI Aug. 6 at 12:22 AM

https://clinicaltrials.gov/study/NCT05363670 $SPRY @Stocktwits Last Update Posted 2026-07-14 Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma ID NCT05363670 Sponsor ARS Pharmaceuticals, Inc. Information provided by ARS Pharmaceuticals, Inc. (Responsible Party)

0 · Reply

LTVI Aug. 4 at 5:31 PM

$SPRY @FantomHive CVS delay, new CEO and major short interest has spanked this…. What investors don’t realize is the new CEO is a commercial operator…Also USA Pediatric addition in March 2026 and all of the EX US approvals are beginning to ramp up. $CVS formulary will be added in due time…early 2027? Regardless CVS stocks this and the new bridge program $199 cash option will keep them rolling in the meantime. This will fly in due time. Current valuation is grossly undervalued.

1 · Reply

FantomHive Aug. 4 at 4:51 PM

$SPRY Bought a position of 1300 shares, feels that a reversal is coming. Revenue growing but stock price falling is kind of weird. I'm sure the stock market will reverse this.

2 · Reply

ae1213 Aug. 4 at 1:09 PM

$SPRY the air was so clean and fresh yesterday without a single post from this “petty demon” @BigGainTom . It is dirty and polluted from early morning today. What a shame …

1 · Reply

MrBean1234 Aug. 3 at 8:21 PM

$SPRY great day…tune out the uneducated knuckleheads who troll this board…insane entry price for 2 year generational wealth exit. GLTA

2 · Reply

LewisDaKat Aug. 3 at 7:00 PM

$SPRY ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results https://marketwirenews.com/stock/spry/news/ars-pharmaceuticals-announces-conference-call-and-we-6986121002929752.html?utm_source=stocktwits

0 · Reply

RolandoJohnson746 Aug. 3 at 2:22 PM

$SPRY $FSLY $LNTH $OCUL $FLNC ARS Pharmaceuticals continues commercial expansion, Fastly focuses on edge computing and cybersecurity, Lantheus benefits from diagnostic imaging growth, Ocular Therapeutix advances ophthalmology treatments, and Fluence Energy expands battery storage deployment.

0 · Reply

MrBean1234 Aug. 3 at 1:38 PM

$SPRY on that gap down to 4.6 SPRY market cap fell below AQST market cap and I scooped up some more. Thank you all again. !!!!!!!

0 · Reply

MrBean1234 Aug. 3 at 1:04 PM

$SPRY I’m buying what anyone is selling. Unreal adds. Thank you all.

0 · Reply

CDCcsd Aug. 3 at 1:02 PM

$SPRY At this price I think it's best to buy it in your IRA, because when it hits $30 you want to sell it and avoid capital gains tax

1 · Reply

parbv Aug. 3 at 12:44 PM

$SPRY Trading like an offering is coming. I like the product but the burn rate is out of control.

0 · Reply

Market Cap	611.71M
Revenue (ttm)	84.28M
Net Income (ttm)	-171.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-203.25%
Debt to Equity Ratio	2.79

Volume	1,330,100
Avg Vol	2,060,136
Day's Range	N/A - N/A
Shares Out	99.30M
Stochastic %K	78%
Beta	0.98
Analysts	Strong Sell
Price Target	$28.67